Besides their potential application in RA, DMARDs and biologics are also associated with numerous side effects such as TNF-α inhibition, which is associated with the risk of tuberculosis [32]; and tocilizumab, which is associated with a risk of lower intestinal perforation [33]. Here, TNF is linked to rheumatoid arthritis.